Crescita Reports First Quarter 2026 Results

• Crescita Therapeutics reported Q1 2026 financial results with total revenue of $5,637k, up from $3,537k in the prior year period.
• Gross profit increased to $2,644k with a gross margin improvement to 46.9% from 44.4%.
• Net loss widened to $(1,160)k compared to $(932)k in Q1 2025, though Adjusted EBITDA turned positive at $238k versus a negative $(679)k previously.
• The company confirmed the pending acquisition by ClinActiv Holdings Inc., with a shareholder meeting scheduled for May 14, 2026, and closing expected in Q2 2026.
• Acquisition terms remain at $0.80 per share (minimum $0.75), representing a ~74% premium over the March 2026 VWAP.
• Operational updates include a five-year lease renewal for manufacturing facilities through September 2031 and continued cash balance of $8,710k.

• The news confirms the execution timeline of the previously announced acquisition (March 2026), reducing uncertainty regarding shareholder approval on May 14.
• Q1 Adjusted EBITDA positivity ($238k) is a material operational improvement over prior periods, signaling better cash generation capability to support operations until deal close.
• The widening Net Loss ($(1,160)k) contrasts with the EBITDA improvement and revenue growth; this suggests higher operating expenses or one-off costs that do not impact the fixed acquisition price but warrant monitoring for standalone viability if deal risk increases.
• Current trading price of $0.76 is only 5% below the offer price of $0.80, indicating the market has largely priced in the transaction; upside is capped by the spread unless working capital adjustments favor shareholders.
• The lease renewal secures operational continuity through 2031, mitigating near-term facility risk but does not impact immediate valuation given the imminent delisting post-close.

• Crescita Therapeutics operates in the skincare and contract manufacturing sector with commercial products and B2B services.
• Flagship assets include the Commercial Skincare segment (revenue $3,049k) and Manufacturing/Services segment (revenue $2,402k).
• Key IP includes the Bacti Control® brand acquired from Laboratoire Provence-Canada Inc. in 2025.
• The company is transitioning to a private entity post-acquisition by ClinActiv Holdings, which will retain core commercial and manufacturing operations.